Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 226

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 226
---
 | ​ | $ |   4,727 |
| MB-109 program costs                                  | ​ | ​                               |     487 | ​ | ​ |   1,140 |
| All other program costs                               | ​ | ​                               |    -641 | ​ | ​ |     548 |
| Research and development - stock-based compensation   | ​ | ​                               |    -650 | ​ | ​ |     132 |
| Research and development - other costs (1)            | ​ | ​                               |   7,845 | ​ | ​ |  33,966 |
| Research and development - licenses acquired          | ​ | ​                               |     861 | ​ | ​ |     527 |
| General and administrative - stock-based compensation | ​ | ​                               |     201 | ​ | ​ |     435 |
| General and administrative - other costs (2)          | ​ | ​                               |   3,934 | ​ | ​ |   9,251 |
| Segment operating loss                                | ​ | $                               |  12,553 | ​ | $ |  50,726 |
| Reconciliation to net loss                            | ​ | ​                               |       ​ | ​ | ​ |       ​ |
| Asset impairment                                      | ​ | ​                               |  -3,692 | ​ | ​ |       - |
| Gain on sale of property and equipment                | ​ | ​                               |       - | ​ | ​ |   1,466 |
| Other income (expense), net                           | ​ | ​                               |     314 | ​ | ​ |     917 |
| Interest income (expense), net                        | ​ | ​                               |     179 | ​ | ​ |  -3,259 |
| Net Loss                                              | ​ | $                               | -15,752 | ​ | $ | -51,602 |

| (1) | Includes expenses primarily related to the repurchase of equipment from uBriGene and termination of existing manufacturing and service agreements with uBriGene, lab supplies and software licenses and subscriptions. |

| (2) | Includes expenses primarily related to outside service costs, business insurance and board of director fees. |

Note 13 – Subsequent Events

Reverse stock split

On January 15, 2025,
the Company filed the Reverse Split Amendment to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary
of State of the State of Delaware to effect the Reverse Stock Split